The federal government is moving toward a major reconsideration of cannabis policy that could have ripple effects across medical research, commercial operations and civil rights. Following an April order from U.S. Attorney General Todd Blanche to reclassify state-licensed medical marijuana from Schedule I to Schedule III, the DEA has scheduled an administrative hearing beginning June 29 in Virginia to evaluate broader rescheduling. Stakeholders from industry leaders to patient advocates and state officials are watching closely as the next procedural steps unfold.

Supporters argue the change is more than symbolic: it would remove long-standing research barriers, create tax relief for medical operators, and prompt regulatory agencies to update policies such as the wording on the ATF Form 4473. Opponents are seeking judicial review; a coalition of state attorneys general filed a petition on May 22 in the U.S. Court of Appeals for the D.C. Circuit contending the AG’s order violates administrative law and international treaties.

Research access and clinical trials

One of the clearest practical outcomes proponents highlight is expanded scientific study. Under the current classification, researchers face strict constraints: they often can only use limited, homogenized plant material from a small number of DEA-licensed research facilities that do not reflect the variety of products available to patients in state programs. Industry executives say moving qualifying medical products to Schedule III will let physicians and investigators test the actual formulations patients use.

Why the change matters for clinicians

Kim Rivers, CEO of Trulieve, has explained that the rescheduling would allow trials using commercially available products, enabling blood-level monitoring, dosing studies and better clinical guidance. She pointed to examples such as a time-release formulation her company developed that could not be properly evaluated under Schedule I restrictions because researchers could not perform the necessary pharmacokinetic testing.

Industry perspectives on research and product development

Executives from other large operators echo that sentiment. Boris Jordan, chairman and CEO of Curaleaf, described the decision as a turning point that would accelerate trials and product maturation. With access to more robust data, companies say they can refine dosing, safety profiles and therapeutic indications for patients enrolled in state programs.

Business, tax and civil-rights implications

Beyond the lab, rescheduling touches several commercial and legal issues. One immediate financial relief cited by industry representatives is potential alleviation of the burdens imposed by Section 280E of the Internal Revenue Code, which currently prevents businesses classified as trafficking controlled substances from deducting ordinary business expenses. The AG’s order indicated tax relief for state-licensed medical operators now, with additional clarification for the broader state-licensed market anticipated later.

Employment and banking effects

Tampa defense attorney Michael Minardi, who handles cannabis-related cases, predicts changes in workplace law: employers may no longer be able to assert that employee use of medical cannabis is illegal, and they may need to treat a Florida physician’s certification similarly to other prescriptions. Rescheduling may also ease access to banking and capital, reducing the reliance on cash-based operations and improving auditing and transparency across the market.

Firearms rules and restoration of rights

Federal agencies have already signaled shifts in related policies. In January, the ATF said it was working to amend the language on Form 4473, which asks about unlawful drug use when determining eligibility to purchase firearms. Advocates such as former Florida Commissioner of Agriculture Nikki Fried framed that as a restoration of rights for medical users, including veterans who rely on cannabis as medication.

Politics, public opinion and legal pushback

Reaction in Florida reflects the broader national debate. Governor Ron DeSantis downplayed the federal move, noting the state’s medical marijuana framework that voters approved in 2016, and emphasizing that federal reclassification may not dramatically change the status quo in the Sunshine State. Still, the politics around legalization remain contested: a 2026 ballot measure to legalize adult recreational use failed to reach the 60% threshold despite majority support.

At the national level, proponents credit outreach and advocacy for influencing federal action. Trulieve’s Rivers has been cited as a key figure in discussions that culminated in the president’s decision to reclassify medical cannabis. Meanwhile, legal opponents continue to challenge the administrative pathway: the May 22 petition by the attorneys general of Indiana, Louisiana and Nebraska seeks to block or overturn the AG’s order on procedural and treaty grounds.

What’s next

The DEA’s hearing beginning June 29 will be a pivotal administrative moment. Advocates say it offers a chance to expand evidence-based policy, while opponents aim to keep the current framework in place. As the process progresses, the practical outcomes—expanded clinical trials, tax adjustments, changes to firearm purchase questions and potential shifts in workplace law—will depend on both regulatory decisions and judicial review. Stakeholders on all sides are preparing testimony and legal arguments that could shape the next phase of federal cannabis policy.

Patient groups, industry leaders and state officials characterize the period as decisive: rescheduling could move the country closer to aligning federal rules with what many states have already adopted, or it could be slowed by lawsuits and regulatory hurdles. Either way, the June hearing marks the next concrete step in a national conversation that spans medicine, commerce and constitutional rights.